$MRCY

Ballhaus William L sold $15.7M of MRCY

Ballhaus William L (Chairman, President & CEO) sold 173,209 shares of MERCURY SYSTEMS INC (MRCY) at an average of $90.59 ($89.47–$93.51, $15.69M total) across 4 trades over 2026-08-21 to 2026-08-24.

Original reporting
SEC EDGAR · Ballhaus William L
Published Aug 25, 2026, 9:53 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 25, 2026, 9:57 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MRCY
Bearish
medium confidence
Mentioned
$MRCY
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MRCYBearishMed
01

Why it matters

The sale reduces insider ownership, potentially affecting perception of insider alignment with shareholders.

02

Market read

Insider sell of $15.7M by CEO may influence short-term price action; watch for market reaction.

03

What to watch

No disclosed reason for sale; could be tax planning or personal liquidity needs.

Relevance 7/10Novelty 7/10Timing: post-market filing

Background

Form 4 filing discloses insider transactions; investors monitor for signals about management confidence.

Company-level read

Ticker impact

$MRCYBearishMedium confidence
Context

CEO William L. Ballhaus sold 173,209 shares for $15.7M, reducing his stake to 299,836 shares.

Expected impact

Possible short-term downside pressure; watch for price dip on volume.

Evidence & confidence

Large insider sale by top executive, but no accompanying negative news; market may interpret as neutral to slightly bearish.

Market effects

Minimal impact on broader tech sector; reflects individual insider activity.

Limited to US markets where MRCY trades.

Low

Counterpoint

Insider sell could be routine diversification; not necessarily a bearish signal.

Key entities

  • William L. Ballhaus

    Chairman, President & CEO of Mercury Systems Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MRCYHighAI 8/10

Mercury Systems (MRCY) Booked $660 Million. Why Did its Shares Fall More than 10% After Hours?

Mercury Systems (MRCY) reported record orders of $660M, up 93.1%, and a 2.28 book-to-bill ratio. Revenue rose 6.1% to $289.8M, beating estimates, but adjusted earnings missed at $0.37 per share. Shares fell over 10% after hours. The company expects fiscal 2027 revenue to approach $1.1B and adjusted EBITDA to approach $200M, but cash flow and margins remain concerns.

$MRCYMedAI 8/10

Mercury Systems Q4 revenue beats estimates as bookings surge

Mercury Systems (MRCY) reported Q4 FY26 revenue of $289.782M, beating estimates by 8.78% but missing EPS expectations. Bookings surged 93.1% YoY to $660M, driving a record backlog of over $1.9B. Management raised FY27 organic growth targets. Analysts raised price targets despite a 10.60% stock drop.

$MRCYMed

Mercury Systems, Inc. Q4 2026 Earnings Call Summary

Mercury Systems reported record Q4 2026 revenue of $660M, driven by strong demand in CPA, effectors, and space applications. Organic growth was 13% domestically, while international revenue declined 15% due to temporary delays. FY 2027 revenue is projected at $1.1B, with low double-digit growth expected. The company partnered with Palantir to enhance operations using AI. Management expects margin expansion and improved cash flow conversion over time, excluding potential upside from munitions and

$MRCYMed

Why Mercury Systems Stock Is Sinking Today

Mercury Systems (MRCY) reported Q4 2026 revenue of $289.8M, beating estimates, but shares fell 6.4% due to EPS miss ($0.37 vs. $0.38) and margin contraction (operating margin down to 5% from 8.6%). Despite record sales and backlog growth, investors are concerned about profitability and valuation.

$MRNAMed

Stocks making the biggest moves premarket: Moderna, Lowe's, Estee Lauder & more

Moderna and Merck shares surged 57% and 6% respectively after positive cancer vaccine trial results. Marvell Technology rose 11% following a $12B Google investment deal. Keysight Technologies gained 2% on better-than-expected Q3 results. Lowe's fell 2% after lowering full-year guidance. Target declined 1.5% despite revenue beats. La-Z-Boy dropped 17% on weak Q1 earnings. Mercury Systems slid 9% on lower revenue forecasts. Toll Brothers rose 1% on Q3 earnings beats. Estee Lauder gained 7% after Q

Ballhaus William L sold $15.7M of MRCY — alphai